8/16/2013

Inovio Pharmaceuticals has announced that its SynCon DNA malaria vaccine elicited lasting antibody and T-cell immune responses in animal studies. A clinical study is expected to begin next year. "We have now generated strong immunology data with our malaria vaccine in nonhuman primates. We are excited to advance toward the very important health care goal of conquering malaria," Inovio President and CEO Dr. J. Joseph Kim said.

Related Summaries